SK Bioscience Co (XKRX:302440) FCF Margin %

: 53.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SK Bioscience Co's Free Cash Flow for the three months ended in Dec. 2023 was ₩48,112 Mil. SK Bioscience Co's Revenue for the three months ended in Dec. 2023 was ₩90,604 Mil. Therefore, SK Bioscience Co's FCF Margin % for the quarter that ended in Dec. 2023 was 53.10%.

As of today, SK Bioscience Co's current FCF Yield % is -0.47%.

The historical rank and industry rank for SK Bioscience Co's FCF Margin % or its related term are showing as below:

XKRX:302440' s FCF Margin % Range Over the Past 10 Years
Min: -44.11 Med: 7.59 Max: 52.97
Current: -5.67

During the past 6 years, the highest FCF Margin % of SK Bioscience Co was 52.97%. The lowest was -44.11%. And the median was 7.59%.

XKRX:302440's FCF Margin % is ranked better than
75.95% of 1031 companies
in the Biotechnology industry
Industry Median: -149.63 vs XKRX:302440: -5.67

SK Bioscience Co FCF Margin % Historical Data

The historical data trend for SK Bioscience Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

6.53

48.77

52.97

-44.11

-5.67

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																25.80	-392.22	-434.46	54.68	53.10

Competitive Comparison

For the Biotechnology subindustry, SK Bioscience Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SK Bioscience Co FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's FCF Margin % falls into.

SK Bioscience Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SK Bioscience Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-20949.128	/	369505.556
	=	-5.67 %

SK Bioscience Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	48112.408	/	90604.217
	=	53.10 %

SK Bioscience Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines